Physician profile
Thomas Tedeschi
NPI 1114551371
$2,588.19
in general payments reported to CMS, 2019-2025
20 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.62 · 2022: $110 · 2023: $416 · 2024: $767 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.55 |
| Education | $135.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $444.31 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $258.76 | 2023-2025 | |
| Astellas Pharma US INC | $219.85 | 2023-2025 | Xtandi, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $219.44 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $204.60 | 2021-2024 | Xiaflex, Aveed |
| Tolmar, INC. | $185.19 | 2023-2025 | Jatenzo, Eligard |
| Endo USA, INC. | $165.65 | 2024-2025 | Aveed, Xiaflex |
| Progenics Pharmaceuticals, INC. | $130.22 | 2023-2025 | Pylarify |
| Ferring Pharmaceuticals INC. | $129.88 | 2024-2025 | Adstiladrin |
| Janssen Biotech, INC. | $112.10 | 2023-2025 | Erleada, Akeega, Balversa |
| Teleflex LLC | $93.14 | 2024-2025 | Barrigel, Urolift |
| 180 Medical, INC. | $92.78 | 2023-2024 | |
| Blue Earth Diagnostics | $76.32 | 2025 | Posluma |
| Dendreon Pharmaceuticals LLC | $67.37 | 2025 | Provenge |
| Antares Pharma, INC. | $50.37 | 2024 | Xyosted |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Halozyme INC | $31.48 | 2023 | |
| Coloplast Corp | $28.84 | 2025 | |
| Calyxo, INC. | $26.05 | 2025 | Cvac Aspiration System |
| Myriad Genetic Laboratories, INC. | $16.78 | 2025 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tedeschi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.